

Differential expression of stromal aromatase in obese females is regulated by DNA methylation

XIAN-CHENG ZENG^{1,2*}, XIANG AO^{3*}, HAI-FENG YANG^{4*}, GUANG-XIAN ZHANG⁵,
WEN-HONG LI¹, QI-LONG LIU¹, YUE-LIANG TANG¹, YI-CHENG XIE¹,
WEN-GUANG HE¹, YAN-NIAN HUANG¹, LEI ZHANG² and RONG-JIANG LI⁶

Departments of ¹General Surgery and ²Clinical Laboratory, Zengcheng People's Hospital (Boji-Affiliated Hospital of Sun Yat-Sen University), Zengcheng 511300; ³Department of Breast Surgery, The Affiliated Cancer Hospital of Guangzhou Medical University, Guangzhou 510095; ⁴Department of Pathology, The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of TCM), Guangzhou 510120; ⁵School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 510006; ⁶Department of General Surgery, Affiliated Xixiang People's Hospital of Guangdong Medical College, Shenzhen 518102, P.R. China

Received September 10, 2013; Accepted March 7, 2014

DOI: 10.3892/mmr.2014.2275

Abstract. Obesity increases the incidence, progression and mortality of breast cancer among postmenopausal females. This is partly due to excessive estrogen production in the adipose tissue of obese females. Aromatase is a key enzyme in estrogen biosynthesis. In the current study, the tensional force-triggered inducibility of aromatase expression was observed to vary in ASCs isolated from different disease-free individuals. In addition, this phenomenon was associated with the activation of the aromatase PII promoter and its DNA methylation load. These findings highlight the impact of tensional forces on estrogen biosynthesis in obese females.

Introduction

Excessive estrogen exposure is a critical risk factor for breast cancer (1). While the ovary is the major site for estrogen biosynthesis in premenopausal females, adipose stromal cells (ASCs) in the breast are a significant source for local estrogen production. Estrogens produced in distal adipose tissues and within the breast tissues affect the growth of breast epithelial cells (2). Notably, excessive local estrogen production in the

breast promotes estrogen-dependent breast cancer. At the molecular level, tumor cell-derived soluble factors, including cytokines and prostaglandin E₂, stimulate the stromal expression of aromatase, a key enzyme in estrogen biosynthesis (3). Breast quadrants bearing malignant tumors consistently exhibit high levels of aromatase activity (4), and breast adipose tissue adjacent to the tumor has a marked increase in aromatase expression and activity (5-7). The clinically proven efficacy of aromatase inhibitors (AIs) in treating estrogen receptor-positive post-menopausal breast cancer indicates the important role of excessive local estrogen production in breast cancer development.

The transcription of the aromatase gene is controlled by a number of tissue and cell type-specific promoters that are located upstream of the aromatase coding region. In cancer-free breast adipose tissue, aromatase mRNA contributions are mainly from the relatively weak I.4 promoter, with a small amount of aromatase mRNA arising from the ovary-specific promoters, I.3 and PII. However, in ASCs adjacent to breast tumors, aromatase expression is activated by the proximally-located promoters, I.3 and PI (2). The switch in promoter utilization from weak I.4 to strong I.3 and PII promoters results in elevated aromatase expression and excessive production of local estrogen (8-9).

It has been shown that mechanical changes, including elevated extracellular matrix (ECM) stiffness and increased interstitial pressures, are associated with epithelial carcinomas. Furthermore, mechanical force due to altered architecture in the tissue microenvironment can affect the gene expression pattern (10-14). In the case of breast cancer, mechanical force significantly affects the invasive behaviors of breast tumor cells, as well as breast cancer incidence and mortality (15-18). The current study, aimed to assess whether ASCs from varying individuals have differential induction levels of aromatase expression responding to mechanical force.

Correspondence to: Dr Rong-Jiang Li, Department of General Surgery, Affiliated Xixiang People's Hospital of Guangdong Medical College, No. 6 Xiyuan Street, Baoan, Xixiang, Shenzhen 518102, P.R. China
E-mail: 18928412937@163.com

Key words: breast cancer, obesity, aromatase, promoter PII, DNA methylation

Materials and methods

Cell culture. Primary human ASCs were isolated from individuals undergoing elective surgical procedures at the University of Virginia (Charlottesville, VA, USA), using methods previously published and approved by the University of Virginia's Human Investigation Committee (21). The cells were cultured in Dulbecco's modified Eagle's medium/F12 medium (Gibco, Big Cabin, OK, USA) with 10% fetal bovine serum (HyClone, Lawrenceville, GA, USA) and 1% antibiotic-antimycotic solution (Gibco), using these previously described methods. Forskolin was purchased from Sigma-Aldrich (St. Louis, MO, USA) and used at a final concentration of 25 μ M. 5-Aza-2'-deoxycytidine (AZA; Sigma-Aldrich) was used at a final concentration of 10 μ M.

3D cultures were conducted in 24-well plates using collagen (collagen bovine type I; BD Bioscience, Franklin Lakes, NJ, USA). Briefly, 2×10^5 cells were suspended in 125 μ l medium and mixed with 125 μ l collagen. Following gel-like 3D structure formation, medium was added to the top.

Aromatase activity assay. Aromatase activity was measured using a tritiated water-release assay as previously described (22). Aromatase activity was determined by the rate of conversion of (1β - 3 H)-androstenedione to estrone by aromatase. The quantity of 3 H in extracts of medium was determined by liquid scintillation counting.

DNA methylation assay. Genomic DNA was obtained using the GenElute Mammalian Genomic DNA Miniprep kit from Sigma-Aldrich. Bisulfite conversion of genomic DNA was performed using the EpiTect Bisulfite kit (Qiagen, Hilden, Germany). PCR, TOPO TA cloning and sequencing (Beckman Coulter Genomics, Danvers, MA, USA) were performed.

Quantitative and semi-quantitative reverse transcription PCR (RT-PCR). Total RNA was isolated using TRIzol reagent (Invitrogen Life Technologies, Carlsbad, CA, USA) according to the manufacturer's instructions. The concentration of RNA was measured and the RNA was reverse-transcribed using the ImProm-II kit (Promega Corporation, Madison, WI, USA). Real-time PCR was performed using the SYBR-Green fluorescent dye and an ABI7900 Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). The forward primer was 5'-TGGAATTATGAGGGCACATCC-3' and the reverse primer was 5'-GTCCAATTCCCATGCAGTAGC-3'. Semi-quantitative RT-PCR was performed using pairs of primers for aromatase transcripts that are specific from promoters I.4, I.3 or PII. GAPDH served as internal control. The PCR conditions were as follows: 94°C for 2 min, 94°C for 30 sec, 56°C for 30 sec, 72°C for 1 min (35 cycles), 72°C for 10 min and then a hold at 4°C. The forward primer sequence for promoter I.3 was 5'-CCTTGTTTTGACTTGTAACCA-3', for promoter I.4 was 5'-GTAGAACGTGACCAACTGG-3' and for promoter II was 5'-GCAACAGGAGCTATAGAT-3'. The reverse primer sequence for all three promoters was 5'-ATTCCCAGTAGCCAGG-3'. The GAPDH forward primer sequence was 5'-CCATCAATGACCCCTTCATTG-3' and the reverse primer sequence was 5'-GACGGTGCCATGGAA TTT-3'.




Figure 1. Differential expression of mechanical force-induced aromatase in ASCs of various individuals. (A) Aromatase activity assay in ASCs from 11 individuals. Sample names are listed along the X axis, while aromatase activity is presented on the Y axis. (B) Collagen-induced aromatase expression in adipose stromal cells. * $P < 0.05$, collagen vs subcon. (C) Promoter utilization was tested by semi-quantitative RT-PCR using the presence of collagen. ASCs, adipose stromal cells; RT-PCR, reverse transcription PCR.

Statistical and data analysis. A paired t-test was used to analyze pairwise comparisons of collagen 3D-cultured cells with control cells. Data from independent measurements were collected for analysis. $P < 0.05$ was considered to indicate a statistically significant difference.

Results

Differential expression of mechanical force-induced aromatase in ASCs of different individuals. The aim of the current study was to determine whether individuals respond to mechanical force differently in terms of aromatase induction.

Stromal cells were isolated from the fat tissue excised from cancer-free individuals. Once growing confluent in regular growth medium, the ASCs were seeded in a 2D or collagen 3D system. The data of the aromatase activity assay showed that there was differential expression of mechanical force-induced aromatase in the different individuals (Fig. 1A). Aromatase mRNA was induced in response to mechanical force (Fig. 1B). In addition, the induction of aromatase expression was regulated by promoter I.3/PII (Fig. 1C).

Higher DNA methylation load of certain CpG sites of the PII promoter corresponds to the lower aromatase activation. Next, the mechanism of differential expression in various individuals was determined. A DNA methylation assay was performed to test the methylation status of aromatase promoter PII (Fig. 2A). The differential induction of aromatase expression is associated with the DNA methylation load




Figure 2. Correlation between DNA methylation status of aromatase promoter region and aromatase inducibility in ASCs of various individuals. (A) CpG sites of aromatase promoter. (B-E) DNA methylation analysis of CpG sites. ASCs, adipose stromal cells.




Figure 3. Reduction of DNA methylation load by AZA treatment restores aromatase activation. (A) mRNA level of aromatase in response to forskolin (FSK) induction following AZA treatment for 4 weeks. (B) DNA methylation assay following AZA treatment for 4 weeks. (C) mRNA level of aromatase in response to forskolin induction following AZA treatment for 8 weeks. (D) DNA methylation assay following AZA treatment for 8 weeks. AZA, 5-Aza-2'-deoxycytidine.

of the promoter region. The higher DNA methylation load of PII promoter is associated with the lower aromatase activation (Fig. 2B-E).

Reduction of DNA methylation load by AZA treatment restores aromatase activation. The cells were treated with AZA for 4 (Fig. 3A and B) or 8 weeks (Fig. 3C and D). Aromatase expression and DNA methylation status were analyzed. Along with reduction of the DNA methylation load, aromatase activation was restored.

Discussion

The current literature on the mechanical properties of tumors is almost exclusively focused on tumor cells (10,12). As altered mechanical homeostasis in breast tumors affects the epithelial and stromal compartments of the same tumor microenvironment, it is necessary to look beyond the 'box' of tumor cells by examining the impact of mechanical forces on the surrounding stroma. Furthermore, ASCs from different individuals may respond to mechanical forces differently, thus, individuals

respond differently to risk factors of breast cancer. The current study data showed that there was differential expression of mechanical force-induced aromatase in differing individuals. It also showed that mechanical force activates the PII promoter and that the DNA methylation status of the PII promoter plays an important role in aromatase induction when ASCs respond to mechanical forces.

The efficacy of AIs in treating breast cancer has been clinically proven. However, AIs indiscriminately reduce estrogen synthesis throughout the body, causing major side-effects, including bone loss, increased fracture rates and abnormal lipid metabolism (21). Thus, it is worthwhile to develop inhibitors that selectively block aromatase and estrogen production in breast cancer. By contrast, aromatase I.3/PII promoters have been reported to be activated in tumors, but not in normal tissues (2). Logically, the specific inhibition of signals that lead to activation of promoter I.3/II is likely to inhibit aromatase expression specifically in tumor tissues. The current study data enhance our understanding of the regulation of aromatase expression in an epigenetic manner. These findings may lead to the identification of novel AIs.

Acknowledgements

This study was supported by the Science and Technology Project Foundation, Science and Technology Commission, Guangdong Province, P.R. China (grant no. 2010B031600147).

References

1. Nass SJ and Davidson NE: The biology of breast cancer. *Hematol Oncol Clin North Am* 13: 311-332, 1999.
2. Bulun SE, Lin Z, Imir G, *et al*: Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment. *Pharmacol Rev* 57: 359-383, 2005.
3. Simpson ER and Davis SR: Minireview: aromatase and the regulation of estrogen biosynthesis - some new perspectives. *Endocrinology* 142: 4589-4594, 2001.
4. O'Neill JS, Elton RA and Miller WR: Aromatase activity in adipose tissue from breast quadrants: a link with tumour site. *Br Med J (Clin Res Ed)* 296: 741-743, 1988.
5. Bulun SE, Price TM, Aitken J, Mahendroo MS and Simpson ER: A link between breast cancer and local estrogen biosynthesis suggested by quantification of breast adipose tissue aromatase cytochrome P450 transcripts using competitive polymerase chain reaction after reverse transcription. *J Clin Endocrinol Metab* 77: 1622-1628, 1993.
6. Harada N: Aberrant expression of aromatase in breast cancer tissues. *J Steroid Biochem Mol Biol* 61: 175-184, 1997.
7. Sasano H and Harada N: Intratumoral aromatase in human breast, endometrial, and ovarian malignancies. *Endocr Rev* 19: 593-607, 1998.
8. Meng L, Zhou J, Sasano H, Suzuki T, Zeitoun KM and Bulun SE: Tumor necrosis factor alpha and interleukin 11 secreted by malignant breast epithelial cells inhibit adipocyte differentiation by selectively down-regulating CCAAT/enhancer binding protein alpha and peroxisome proliferator-activated receptor gamma: mechanism of desmoplastic reaction. *Cancer Research* 61: 2250-2255, 2001.
9. Zhou J, Gurates B, Yang S, Sebastian S and Bulun SE: Malignant breast epithelial cells stimulate aromatase expression via promoter II in human adipose fibroblasts: an epithelial-stromal interaction in breast tumors mediated by CCAAT/enhancer binding protein beta. *Cancer Research* 61: 2328-2334, 2001.
10. Avvisato CL, Yang X, Shah S, Hoxter B, Li W, Gaynor R, Pestell R, Tozeren A and Byers SW: Mechanical force modulates global gene expression and beta-catenin signaling in colon cancer cells. *J Cell Sci* 120: 2672-2682, 2007.
11. Shyy JY and Chien S: Role of integrins in endothelial mechanosensing of shear stress. *Circ Res* 91: 769-775, 2002.
12. Alenghat FJ and Ingber DE: Mechanotransduction: all signals point to cytoskeleton, matrix, and integrins. *Sci STKE* 2002: pe6, 2002.
13. Lopez JJ, Mouw JK and Weaver VM: Biomechanical regulation of cell orientation and fate. *Oncogene* 27: 6981-6993, 2008.
14. Nelson CM and Bissell MJ: Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. *Annu Rev Cell Dev Biol* 22: 287-309, 2006.
15. Paszek MJ and Weaver VM: The tension mounts: mechanics meets morphogenesis and malignancy. *J Mammary Gland Biol Neoplasia* 9: 325-342, 2004.
16. Ingber DE: Can cancer be reversed by engineering the tumor microenvironment? *Semin Cancer Biol* 18: 356-364, 2008.
17. Le Beyec J, Xu R, Lee SY, Nelson CM, Rizki A, Alcaraz J and Bissell MJ: Cell shape regulates global histone acetylation in human mammary epithelial cells. *Exp Cell Res* 313: 3066-3075, 2007.
18. Wiseman BS and Werb Z: Stromal effects on mammary gland development and breast cancer. *Science* 296: 1046-1049, 2002.
19. Katz AJ, Tholpady A, Tholpady SS, Shang H and Ogle RC: Cell surface and transcriptional characterization of human adipose-derived adherent stromal (hADAS) cells. *Stem Cells* 23: 412-423, 2005.
20. Yue W and Brodie AM: Mechanisms of the actions of aromatase inhibitors 4-hydroxyandrostenedione, fadrozole, and aminoglutethimide on aromatase in JEG-3 cell culture. *J Steroid Biochem Mol Biol* 63: 317-328, 1997.
21. Morales L, Neven P and Paridaens R: Choosing between an aromatase inhibitor and tamoxifen in the adjuvant setting. *Curr Opin Oncol* 17: 559-565, 2005.